Senseonics Holdings, Inc. filings document the public-company disclosures of a medical technology issuer commercializing implantable continuous glucose monitoring products for diabetes care. Its Form 8-K reports furnish operating results and business updates for Eversense CGM systems, including commercialization activity, clinical or regulatory disclosures, product integrations and financial outlook commentary.
The company’s regulatory record also covers capital-structure and financing matters, including public offerings of common stock and pre-funded warrants and amendments to debt arrangements. Proxy materials disclose board elections, executive compensation votes, auditor ratification, authorized-share proposals and equity incentive plan matters. A Form 25 filing documents the voluntary withdrawal of Senseonics common stock from listing and registration on NYSE American.
Senseonics Holdings, Inc. insider reports routine share withholding for taxes. A director and Chief Medical Officer filed a Form 4 showing the disposition of 4,605 shares of common stock on 11/15/2025 at $6.26 per share, coded as an "F" transaction, meaning shares were withheld to cover tax obligations upon vesting of restricted stock units. After this transaction, the insider beneficially owned 123,948 shares of Senseonics common stock. The company effected a 1-for-20 reverse stock split of its common stock effective October 17, 2025, and the share amounts reported in this filing have been adjusted to reflect that reverse split.
Senseonics Holdings, Inc. (SENS) reported an insider equity transaction by its Chief Operating Officer on a Form 4. On 11/15/2025, 10,317 shares of common stock were withheld and disposed of at $6.26 per share to cover withholding tax obligations tied to the vesting of restricted stock units. After this tax-related transaction, the reporting person beneficially owned 259,979 shares of common stock directly. The company also notes that, effective October 17, 2025, it implemented a 1-for-20 reverse stock split, and all share amounts in the report have been adjusted to reflect this reverse split.
Senseonics Holdings, Inc. (SENS) reported an insider equity transaction by its GC & Corp. Development Advisor on a Form 4. On 11/15/2025, 5,997 shares of common stock were withheld at $6.26 per share to cover withholding taxes upon the vesting of restricted stock units. Following this transaction, the reporting person beneficially owned 144,434 shares of common stock in direct ownership form.
The filing also notes that, effective October 17, 2025, Senseonics implemented a 1-for-20 reverse stock split of its common stock, and the share numbers in the report have been adjusted to reflect this reverse split.
Senseonics Holdings, Inc. (SENS) reported an insider equity transaction by its President and CEO, who is also a director. On 11/15/2025, the executive disposed of 27,067 shares of common stock at $6.26 per share, coded "F" for a tax-related withholding event.
After this transaction, the executive directly beneficially owned 634,018 shares of Senseonics common stock. The filing explains that the shares were withheld to satisfy withholding tax obligations upon the vesting of restricted stock units, meaning the disposition was tied to equity-compensation taxation rather than an open-market sale.
Senseonics Holdings, Inc. filed Form 25, notifying the removal of its Common Stock ($0.001 par value) from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934 on the NYSE American. This filing signals the company’s intent to delist its common shares from that exchange pursuant to the Exchange Act’s procedures.
Senseonics Holdings (SENS): A company director reported an open‑market purchase of common stock on 11/10/2025. The filing shows 10,000 shares acquired at a weighted average price of $6.55, with individual trades executed between $6.48 and $6.58. Following this transaction, the director beneficially owned 74,708 shares, held directly.
The share counts reflect the issuer’s 1‑for‑20 reverse stock split that became effective on October 17, 2025.
Senseonics Holdings (SENS) director reported an open‑market purchase of common stock. On 11/07/2025, the insider bought 15,000 shares at $5.83 per share (Transaction Code P). Following the trade, the insider beneficially owns 99,727 shares, held directly. A footnote states that, effective October 17, 2025, the company completed a 1‑for‑20 reverse stock split, and the reported share amounts reflect this adjustment.
Senseonics Holdings (SENS): CFO insider purchase reported. The Chief Financial Officer bought 5,415 shares of common stock on 11/07/2025, reported with Transaction Code P. The weighted average purchase price was $5.88 per share, from multiple trades ranging from $5.8401 to $5.885.
Following the transaction, the reporting person beneficially owns 157,028 shares, held directly. The share counts reflect the issuer’s 1-for-20 reverse stock split effective October 17, 2025.
Senseonics Holdings (SENS) reported an insider purchase on Form 4. A reporting person who serves as President, CEO, and Director bought 17,210 shares of common stock on 11/07/2025 at a weighted average price of $5.87.
Following the transaction, the filer beneficially owns 661,085 shares, held directly. The company effected a 1-for-20 reverse stock split on October 17, 2025, and the reported share amounts reflect this adjustment. The price reflects multiple trades between $5.80 and $5.90.
Senseonics Holdings, Inc. filed its Q3 2025 10‑Q, reporting total revenue of $8.1 million, up from $4.3 million a year ago, and a net loss of $19.5 million. Gross profit was $3.5 million versus a gross loss in the prior year period.
The company ended the quarter with $111.0 million in unrestricted cash, cash equivalents and marketable securities. Management disclosed that substantial doubt exists regarding its ability to continue as a going concern, citing expected cash needs and covenant requirements under its amended loan agreement.
Senseonics amended its term loan facility on September 3, 2025, increasing capacity to $100.0 million (maturing September 3, 2029) with a minimum cash covenant. It also raised capital via a $57.5 million public offering and a concurrent $20.3 million private placement with Abbott in May, and established a $100.0 million at‑the‑market program in August. A 1‑for‑20 reverse stock split became effective on October 17, 2025. The company signed an MOU with Ascensia to transition Eversense commercialization back to Senseonics beginning January 1, 2026.